Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

Priyadarshini Balasubramanian Christoph WannerJoão Pedro FerreiraAnne Pernille OfstadAmelie ElsaesserBernard ZinmanSilvio E Inzucchi

Published in: The Journal of clinical endocrinology and metabolism (2022)

Compared with placebo, empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2D patients. The underlying mechanisms are unknown but may involve altered lithogenic profile of the urine. Dedicated randomized prospective clinical trials are warranted to confirm these initial observations in patients with and without T2D.

Keyphrases

clinical trial
urinary tract
end stage renal disease
double blind
phase iii
ejection fraction
newly diagnosed
chronic kidney disease
open label
placebo controlled
phase ii
prognostic factors
peritoneal dialysis
randomized controlled trial
patient reported outcomes
bone marrow
patient reported